



Tina S Morris, PhD

200 Ocean Trail Way, #303, Jupiter FL 33477
T: +1-240-731-2847 E: nuerburging@hotmail.com

Academic Training

Postdoctoral researcher, National Institute of Allergy, and Infectious Diseases

National Institutes of Health (NIH), Bethesda

July 1994 – February 1997

Research on Hepatitis A Virus Proteinase 3C and potential inhibitors for viral replication in the laboratory of Robert H. Purcell. US patent for the development of an ELISA method employing HAV proteinase 3C.

Ph.D., molecular virology

Medical University of Luebeck, Germany

January 1992 – June 1994

Research focused on the Hepatitis A Virus Proteinase 3C and viral polyprotein processing. PhD thesis awarded with the Otto Roth Award of the university, summa cum laude graduation.

BSc and MS in Biology

Carl von Ossietzky University, Oldenburg, Germany

October 1986 – December 1991

Management and Leadership Training

Center for Creative Leadership

Leadership Development Program (LDP)

2009

Leadership for Organizational Impact (LOI)

2015

Publications

<https://orcid.org/0000-0002-1112-1516>

https://www.researchgate.net/profile/Tina_Morris3/publications

Board/Advisory Appointments

Scientific Advisory Board member at the National Institute for Biological Standards and Control (NIBSC), an agency of the UK regulatory authority (MHRA), since 2014

https://www.nibsc.org/about_us/scientific_advisory_committee.aspx

British Pharmacopeia Analytical QbD Working Party, since 2021

<https://www.pharmacopoeia.com/technical-advisers-to-the-bpc>

Ocean Trail Condominium Association #1, Board of Directors Vice President, since 2023



Experience

American Association of Pharmaceutical Scientists (AAPS)

Executive Director

April 2020 to current

Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide. As the Executive Director, chief executive, and member of the Board of Directors, the ED leads the staff team that supports all operational aspects of the Association and works with the AAPS Board of Directors and other Volunteer Leadership Committees on the strategic and direction-setting activities that guide the work of the scientific society.

Accomplishment highlights to date: leadership of AAPS through a successful complete virtual pivot during the COVID19 pandemic and transition to a strong year-round scientific engagement and content strategy, simultaneously guiding the completion of a new strategic plan with the AAPS volunteer leadership. Immediately set the plan implementation in motion and developed operational and governance mechanisms to establish disciplined innovation and planning mechanisms at AAPS. Greatly expanded AAPS' digital scientific content offerings and began building a modern, comprehensive, science-first governance structure that includes a new scientific advisory committee and associated task forces, with the intent of revitalizing AAPS's science while building on and protecting the organization's existing strong reputation. Strengthened AAPS' focus on a broad and diverse member volunteer talent pipeline with the help of a new DEI Committee. Established a Scientific Advisory Committee to strategically guide AAPS' scientific future and relevance path. Greatly reduced AAPS' expenses by making the organization's operations fully virtual, improving event performance, and optimizing contracted services. Successfully secured two rounds of PPP loan funding and assured complete loan forgiveness, boosting AAPS' fiscal viability during a time when member associations have been facing significant challenges. Successfully reintroduced the National Biotechnology Conference that has been experiencing strong year-over-year growth since then. Increased ROI on existing conferences and restructured meeting formats for greater scientific and business success. Increased membership again after years of decline and improved member retention by over 20%.

Parenteral Drug Association (PDA)

Vice President, Scientific & Regulatory Affairs

June 2018 to April 2020

As Head of PDA's Science & Regulatory Department, oversaw the development of PDA's well-known and widely relied upon portfolio of technical documents – the Technical Report Series, Books, Points to Consider, and Standards through the work of PDA's Volunteer Advisory Boards, Task Forces, and Technical Report Teams. This also included domestic and international regulatory commenting, as well as the development of programming for scientific conferences and education courses globally. As part of the position directed PDA technical staff responsible for managing PDA's technical volunteer bodies. As a member of the PDA senior leadership team reporting to the President and CEO, the position also provided input into the organization's strategy development and implementation through interaction with the Board of Directors.



Experience

United States Pharmacopeia (USP)

Senior Vice President, Compendial Science

February 2017 to May 2018

Member of the USP Global Leadership Team (GLT). The position oversaw USP's General Policies and Requirements space, as well as international pharmacopeial harmonization and collaboration, this role was both internationally visible, deeply strategic and involved direction-setting decision making about the future structure and architecture of high impact and broadly applicable standards for pharmaceutical quality. This included widely mandatory requirements for key pharmaceutical impurities as well as other enforceable standards applicable to a wide segment of the pharmaceutical industry in direct dialog with industry experts, as well as national and international regulators. The position directed senior staff managing expert committees as well as several senior cross-functional teams charged with evolving USP's future scientific policy direction.

United States Pharmacopeia (USP)

Senior Vice President, Global Biologics

May 2015 – February 2017

In this role, the full integration of USP's rapidly expanding global scientific and laboratory resources for biologics into a single, highly productive business unit was accomplished with over 50 staff in the US, India, and China. This resulted in further establishing USP's presence in the modern, biotechnology space with industry-relevant standards for a broad range of biologics, from innovative latest generation therapies to the modernization of requirements for legacy biologics. Charted USP's scientific and policy approach to develop standards for high impact multi-manufacturer biologics and biosimilars and introduced the concept of broadly applicable analytical performance standards to increase relevance of standardization early in the biopharmaceutical development lifecycle.

United States Pharmacopeia (USP)

Vice President, Global Biologics

February 2009 – May 2015

Expanded biologics and biotechnology as an innovative and relevant standard-setting program at USP by introducing new approaches, formats, and development paths for non-traditional standards. Established critical scientific and policy alliances with key international standard-setting organizations like the National Institute for Biological Standards and Control (NIBSC), the World Health Organization (WHO) and others to expand USP's access to expertise and grew in-house laboratory capabilities in USP's own biologics laboratory in Rockville, as well as a newly created laboratory in Hyderabad, India. Established collaborative working procedures and new development pathways for standards, adapted existing working paradigms for chemical standards to fit new needs, fostered new ways of working across functional areas to enable critical new capabilities that previously did not exist.

United States Pharmacopeia (USP)

Director, Biologics & Biotechnology

January 2006 – February 2009

Began building a dedicated biologics and biotechnology standard-setting program at USP with an initially small nucleus of staff. A major accomplishment was the full modernization of one of USP's highest impact standards in biologics, the USP Heparin Sodium monograph, in response to the heparin adulteration crisis of 2007 and 2008. In close collaboration with FDA, the modernization of this key standard resulted in securing the US unfractionated and low-molecular weight heparin supply while avoiding drug shortages and preventing future harm to patients taking a life-saving medicine. Other accomplishments included the establishment of USP's first dedicated biologics and biotechnology laboratory at the organization's main campus in Rockville.

United States Pharmacopeia (USP)

Senior Scientific Liaison, Vaccines & Virology

November 2003 – January 2006

Responsible for the standard-setting activities of USP's Vaccines, Virology, and Immunology Expert Committee. Revived a large dormant standard-setting area with many outdated and industry-irrelevant standards to include more modern approaches and a fresh set of expertise. Initiated a



broader dialog around standards for biologics, including more modern and relevant standards for key legacy biologics.

Human Genome Sciences, Inc.

Senior Scientist and Group Leader, Protein Development

July 1998 – November 2003

Responsible for analytical development supporting HGS's clinical development programs at pre-IND, as well as phase 1 through phase 3 stages for recombinant therapeutics candidates – initially growth factors and hormones, later a large variety of recombinant humanized and modified monoclonal antibodies. Developed and validated characterization and release assays and performed in-depth product characterization. Key analytical expertise areas include protein separations, glycoprotein and glycan analysis, mass spectrometry.

Ciphergen Biosystems, Inc.

Field Scientist, analytical development

February 1997 – July 1998

Working in a small company innovative start-up environment, this role was focused on the development of novel approaches to affinity mass spectrometry. Working with a new instrumentation, software, and consumables platform, the position involved de novo method development, in-project trouble-shooting and extensive bridging to existing technology. US patent for affinity capture surface-enhanced laser desorption mass spectrometry.